New Parkinson's drug enters early human testing

NCT ID NCT06565195

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests a new drug called LY3962681 in healthy volunteers and people with Parkinson's disease. The goal is to check if the drug is safe and how the body processes it. Participants receive either the drug or a placebo injected into the spinal fluid, and are followed for up to a year.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PARKINSON'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Parkinson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Austin Clinic PPD

    RECRUITING

    Austin, Texas, 78744-1625, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Ehime University Hospital

    NOT_YET_RECRUITING

    Tōon, Ehime, 791-0295, Japan

  • Oita University Hospital

    NOT_YET_RECRUITING

    Yufu, Oita Prefecture, 879-5593, Japan

  • P-One Clinic, Keikokai Medical Corporation

    RECRUITING

    Hachiōji, Tokyo, 192-0071, Japan